SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ADMEDUS LTD (AHZ)

Former Name ASX

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 FROMTO
ANTERIS TECHNOLOGIES LTD22/05/2020
ADMEDUS LTD25/11/201322/05/2020
ALLIED HEALTHCARE GROUP LTD01/07/201125/11/2013
BIOMD LIMITED01/07/2011

Shareholder links

Our website ranking of AHZ: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare, Level 11, 172 St Georges Terrace, Perth WA 6000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

Address: Toowong Tower Level 3, 9 Sherwood Rd Toowong QLD 4066
Tel:  +61 (0)8 9266 0100 Fax: +61 (0)8 9266 0199

Date first listed: 24/03/2004
Company Secretary: Steve Denaro
Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Innovative Healthcare Solutions - developing, investing and delivering leading edge medical technologies

name changed to Anteris Technologies Ltd

22/05/2020

The suspension of trading in the securities of Admedus Limited will be lifted immediately, following the release by AHZ of an announcement a recapitalisation plan.

14/10/2019

Admedus has sold the distribution rights to its CardioCel and VascuCel product range for $A36.2 million (including all earnouts) to LeMaitre Vascular Inc. $A22.8M upfront payment plus two instalments of $A1m each after 12 months and 36 months. Up to $A11.4M on earn-out payments for a total $A36.2M (at the current $US0.67/$A1 rate), subject to achievement of certain milestones. Up to 3-year manufacturing contract with 20% margin above cost to AHZ . Retain entire IP portfolio for ADAPT enabling continuation of product development pipeline. Transitions Admedus to focus on advancing its Transcatheter Aortic Valve Replacement programme and other potential products. The transaction is non-dilutive, underpinned by manufacturing revenues and reduced operating expenses and headcount .

14/10/2019

The company expects the suspension to last until the earlier of the commencement of normal trading on 15 October 2019, or the release of an announcement by the company in relation to the broader recapitalisation plan.

30/09/2019

The company has received regulatory approval for the sale of the CardioCel 3D product portfolio in Israel. The approval allows the company to service a greater segment of the market with a solution for the repair of high-complexity congenital heart defects.

04/09/2019

The company expects the suspension of its securities to last until the earlier of the commencement of normal trading on 30 September 2019 or the release of an announcement in relation to the broader recapitalisation plan.

02/09/2019

The company lodges its Appendix 4D and Half Yearly Financial Report.

23/08/2019

The company has not paid their annual listing fees in respect of the year ending 30 June 2020 but the securities are already suspended from official quotation.

22/08/2019

The company issues a response to ASX Appendix 4C Query.

15/08/2019

The company has received notice from acromed ag of its intention to terminate the distribution agreement with Admedus for the supply of acromed branded products in Australia and New Zealand.

08/08/2019

The company requests a further extension to the voluntary suspension of the quotation of its ordinary securities. The voluntary suspension is necessary for the company to finalise the next phase of the recapitalisation plan which has progressed but has not yet been finalised. The suspension is expected to to last until the earlier of the commencement of normal trading on 2 September 2019, or the release of an announcement.

05/08/2019

The company lodges its Appendix 4C - quarterly.

31/07/2019

The company requests for an extension to the voluntary suspension of its securities to finalise the next phase of its recapitalisation plan. The suspension is expected to last until the earlier of the commencement of normal trading on 5 August 2019, or the release of an announcement.

01/07/2019

The company announces the publication of an independent study assession the performance of CardioCcel in the prestigious peer-reviewed journal, The Annals of Thoracic Surgery.

24/06/2019

The company requests a further extension to the voluntary suspension of its securities to finalise the next phase of its recapitalisation plan. The suspension is expected to last until the earlier of the commencement of normal trading on 1 July 2019, or the release of an announcement in relation to the recapitalisation plan.

04/06/2019

BTC health completes acquisition of hospital infusion business for $6.3 million.

31/05/2019

Admedus confirms completion of the sale of part of its Infusion business to BTC Speciality Health Pty Ltd, a wholly owned subsidiary of BTC Health Limited for A$6.3 million.

31/05/2019

The company requests a further extension to the voluntary suspension of the quotation of its ordinary shares. The suspension is expected to last until the earlier of the commencement of normal trading on 4 June 2019, or the release of an announcement by the company in relation to its broader recapitalisation plan.

21/05/2019

The company releases the results of its 2019 Annual General Meeting.

14/05/2019

The company releases its 2019 AGM Presentation.

14/05/2019

BTC Health releases an announcement. BTC health takes decisive step to become a leading supplier of innovative medical products. Acquisition of exclusive rights to ambIT range of infusion pumps for Australia and New Zealand. Forecast annual revenues of $7 million p.a. and growing at 14% p.a. Purchase price of $6.3 million which includes $1.75 million of working capital. Establishes a platform for anticipated strong growth and new product introductions commencing 2H2019.

13/05/2019

The company has entered into an agreement to sell part of its Infusion business to BTC Speciality Health, a wholly owned subsidiary of BTC Health Lmited, for $6.3 million. This will complete the first phase of the Infusion business divestiture. Completion of the sale is subject to certain conditions being satisfied with the sale expected to complete in late May 2019.

13/05/2019

The company has entered into a facility agreement with SIO Partners for a secured debt facility of A$1 million. The proceeds will provide funds for general working capital and operational costs. The company will continue with the restructure of the business operations to reduce certain overhead costs, and a proposed divestment of the infusion business so as to capitalise on its growing ADAPT business.

08/05/2019

The company requests a further extension to the voluntary suspension of its securities to finalise the next phase of its recapitalisation plan. The suspension is expected to last until the earlier of the commencement of trading on 21 May 2019 or the release of an announcement.

07/05/2019

The company lodges its Appendix 4C - quarterly.

26/04/2019

The company requests a further extension to the voluntary suspension of its securities until the earlier of the commencement of trading on 7 May 2019 or the release of an announcement regarding the next phase of the recapitalisation plan.

23/04/2019

The share sale agremeent entered into by its wholly owned subsidiary, Admedus Investments with Constellation Therapeutics and the other sharheolders of Admedus Vaccines for the sale of all of the shares of Admedus Vaccines has been terminated. The Admedus Vaccines board of directors has appointed Peter Anthony Lucas of P A Lucas & Co Pty Ltd as voluntary administrator of Admedus Vaccines. AHZ gives notice that Resolution 6 included in the notice of AGM is withdrawn and will not be considered by shareholders at the AGM.

23/04/2019

The company issues a response to ASX Aware Query.

23/04/2019

The securities of Admedus Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHZ, pending the release of an announcement regarding the Immunotherapies Transaction.

17/04/2019

The suspension of trading in the securities of Admedus Ltd will be lifted immediately, following the release by AHZ of an announcement regarding a capital raising.

28/11/2018

The company issues a prospectus for a pro rata renounceable partially underwritten entitlement offer of 5 New Shares for every 7 Existing Shares held at an issue price of $0.08 per New Share to raise up to $20.2 million. Each New Share includes one free attaching New Option with an exercise price of $0.08 that expires three years from the date of issue. The Entitlement Offer is partially underwritten for $9.1 million and commitments have been received from existing Shareholders for a further $4 million. Up to a further $6.3 million in underwriting will be provided if Admedus Limited does not raise a minimum amount under the Entitlement Offer.

28/11/2018

Admedus announces a pro rata renounceable partially underwritten entitlement offer to raise up to $20.2 million before costs. Based on underwriting and commitments received by Admedus, the Entitlement Offer is expected to raise a minimum cash amount of $12 million after the payment of underwriter fees and repayment of a $5 million loan to major shareholder Star Bright. Offer of 5 new fully paid ordinary shares for each 7 shares currently held with an attaching option for each new shares issued. The offer price of $0.08 per New Share represents a discount of: 40.74% to the last traded price of shares on ASX on 1 August 2018 of $0.135; and 38.6% to the volume weighted average issue price paid by Star Bright Holding Ltd under the recent placement completed on 5 September 2018 of $0.112. Attaching options will be listed with an 8 cent exercise price and three year exercise period.

28/11/2018

The company lodges its Appendix 4C - quarterly.

01/11/2018

The company expects the suspension to last until the release of an announcement in relation to the broader recapitalisation plan.

03/09/2018

The company lodges its Appendix 4D and Half Yearly Financial Report.

03/09/2018

Cornerstone strategic investor secured, raising up to $7.7 million. $5 million unsecured loan facility was entered into with Star Bright, repaying Partners For Growth facility. Company restructure and recapitalisation plan in development.

03/09/2018

The company expects that the suspension of its securities will last until the earlier of the commencement of normal trading on 3 September 2018, or the release of an announcement by the company in respect of the company's capital raising as well as a broader recapitalisation of the company.

20/08/2018

The compan requests a further extension to the voluntary suspension of its securities. This is expected to last until the earlier of the commencement of normal trading on 20 August 2018, or the release of an announcement by the Company.

13/08/2018

The company has renewed its exclusive distribution agreement with Utah-based Summit Medical Products Inc. (Summit) for a further eight years. Under the terms of the extended agreement, Admedus remains the exclusive distributor of Summit's ambIT infusion products in Australia and New Zealand until 2026.

09/08/2018

The company expects the suspension of its securities to last until the earlier of the commencement of normal trading on 13 August 2018, or the release of an announcement regarding a capital raising.

08/08/2018

The securities of Admedus Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company, pending the release of an announcement regarding a Placement with potential investors in respect of the capital raising.

06/08/2018

we understand that on or about this date the company consolidated its shares 1 for 10

26/11/2015

name changed from Allied Healthcare Group Ltd

25/11/2013

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    04/03/2016Wayne Paterson30,000$0.560$16,800

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    John SeabergChairman, Independent Director10/10/2014
    Wayne PatersonCEO, Managing Director10/10/2014
    David St. DenisCOO09/06/2017
    Matthew McDonnellCFO23/11/2018
    Yanheng WuNon Exec Director12/12/2018
    Wenyi GuNon Exec Director04/10/2018
    Steve DenaroNon Exec Director31/10/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Lishan ZhangNon Exec Director12/12/201830/05/2019
    Catherine CostelloExecutive Director, CFO01/11/201716/11/2018
    Simon BuckinghamNon Exec Director17/02/201704/10/2018
    Mathew RattyNon Exec Director27/05/201620/05/2018
    Mark ZiirsenCFO26/08/201601/11/2017
    Julian ChickCOO01/01/201209/06/2017
    Michael BennettExecutive Director16/07/200317/02/2017
    Stephen MannCFO10/10/201126/08/2016
    Lee RodneManaging Director, CEO16/06/201130/06/2016
    Chris CatlowChairman16/06/201109/02/2016
    Graeme RowleyNon Exec Director16/06/201109/02/2016
    Peter TurveyIndependent Director18/05/201208/02/2016
    Jet SoedirdjaNon Exec Director16/06/201118/05/2012
    Robert TownerNon Exec Director16/07/200303/04/2012
    Robert ScottNon Exec Chairman23/06/199916/06/2011

    Date of first appointment, title may have changed.